Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of

GlobeNewswireMay 10 21:35

Immix Biopharma | 10-Q: Quarterly report

Futu NewsMay 10 04:33 · Announcements

Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment

Immix Biopharma (IMMX) said Monday that the European Commission has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma. The designation qualifies NXC-201 among others for

MT NewswiresApr 30 02:50

Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In Multiple Myeloma

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol

BenzingaApr 29 21:39

Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year

Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation v

MT NewswiresApr 19 04:12

Immix Biopharma on Track to Dose NXC-201 Patients in United States

Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No

GlobeNewswireApr 18 21:32